MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, October 4, 2014

Biogen’s new MS drug to cost $62,036 a year


  | GLOBE STAFF   OCTOBER 04, 2014
Cambridge biotech Biogen Idec Inc. said Friday it will charge $62,036 per patient for a year’s treatment with its newly approved multiple sclerosis drug Plegridy.
The list price of Plegridy, a new type of injectable drug that treats adults with the most common form of MS, is identical to that of Biogen Idec’s original injectable, Avonex, which is still on the market.
Plegridy, a longer-lasting drug for patients with relapsing-remitting MS, was approved by the Food and Drug Administration on Aug. 15 for US sale. Biogen Idec disclosed the price Friday before releasing the drug to distributors.
“We’re pricing for the innovation,” said Biogen Idec spokeswoman Kate Niazi-Sai. “But we’re also pricing to make sure patients have access to it and the system can support it. That’s a balance, and that’s what we’re trying to do here.”
Drug pricing has become a hot button issue in an era of rising health costs.
Payments for Sovaldi, a $1,000-a-day pill to treat hepatitis C, has strained the finances of health insurers. Sovaldi, sold by California-based Gilead Sciences, costs $84,000 for a three-month treatment regimen. Last month, another Cambridge biotech, Genzyme, priced its new pill to treat Gaucher disease at $310,250 a year for the small population of US patients suffering from the rare genetic disorder.

 Keep CURRENT and up to date, 
Sign-Up for our email


No comments: